Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Core Insights - Biogen reported a financial loss due to a significant decline in revenue from its primary multiple sclerosis treatments, indicating challenges in its core business operations [1] Company Performance - The company experienced a double-digit percentage decline in revenue from its multiple sclerosis treatments, which are crucial to its financial health [1]